Applied UV,
Inc.
Subsidiary,
SteriLumen,
Inc.
Enters into
Exclusive
Distribution Agreement
with
Akida Holdings LLC,
for its
Airocide™
Air Quality-Improvement™ System
SteriLumen
Will Become Distributor in the U.S
and the Greater
Middle East
to the Hospitality and Hotel Industry
Mount
Vernon,
NY
-- September 8, 2020 -- InvestorsHub NewsWire
-- Applied
UV,
Inc. (NasdaqCM:
AUVI)
("Applied
UV" or the "Company"), an infection prevention technology company
that applies the power of narrow-range ultra violet
light
("UVC")
utilizing
its patented devices to destroy pathogens
safely, thoroughly, and automatically, today
announced that its
subsidiary, SteriLumen,
Inc.
("SteriLumen"),
has signed an
exclusive
distribution
agreement with Akida Holdings LLC
for its
Airocide™
Air Quality-Improvement™ System (Airocide System)
line of
patented,
air
purification technologies
for use in the
hospitality and hotel industries
in the US and Greater Middle East.
The
Airocide™
system,
originally
developed
for
NASA
by the University of Wisconsin,
is an
airborne pathogen killing technology that uses a patented
combination of
UVC
and a proprietary,
titanium
dioxide
based photocatalyst.
Listed
as
an FDA
Class
II
Medical
Device,
the
Airocide™
technology
is clinically proven and field tested to kill/remove/eliminate
airborne pathogenic and non-pathogenic
microorganisms,
allergens, odors and harmful VOC's in
a variety of
applications and industries
including healthcare, hospitality,
grocery
chains,
wineries,
commercial real estate,
schools,
dental offices,
cannabis, and homes.
Airocide™
has been featured on "CNN", "Fox News Networks", "Maxim" and "The
Ellen Show".
The
Airocide™
technology
has been widely adopted
and
is
currently
used by nationally recognized brands
such as
Delmonte,
Opus One,
DiMare,
and
Davis Estates Winery,
to name a few.
Under the
terms of the agreement, SteriLumen,
within the hotel and hospitality markets, will be
the
exclusive distributor
of
Airocide™
systems
in
the U.S.
and the
Greater Middle East. The
combination of SteriLumen
and
Airocide
disinfecting
solutions
allows SteriLumen
to
provide customers a broader
range
of disinfection
solutions and products.
"We
believe we have found a perfect partner as both companies' focus is
innovation and the commitment to understand and deliver solutions
to our customers," said
Max
Munn,
President
of Applied UV. "Indoor
air quality is a critical need for virtually all public
spaces, and especially so for healthcare facilities, hotels and
restaurants due to the continuous
exposure of bacteria and
viruses
they are confronted with daily.
We
believe the Airocide™
system is
the right solution to safely
reduce
airborne pathogens. We
are
excited about offering our customers a comprehensive
set of solutions to
address the very serious challenges posed by
the
current pandemic and by pathogens in the air
and on surfaces."
Keith
Frein, President &
CEO of
Airocide™
added,
"We
are pleased to welcome
SteriLumen
as
a
distribution partner for the Airocide family of products.
SteriLumen
is
an
ideal partner for
the Airocide
brand
as
they have the scale,
infrastructure, reputation, experience, and complementary
product portfolio to expand the
Airocide™
family
of products
into new
markets, adding to our expanding
market
leadership position."
Q
Saeed,
Chief
Executive Officer of Applied UV, commented, "The
Airocide™
team
has already been a great partner with an opportunity
for
business development in
the United
Arab Emirates.
Airocide™
systems
are
already being
utilized in
some hospitals and healthcare facilities worldwide. We see it as a
complimentary solution in hospitality and
healthcare sector,
as
SteriLumen is
focused
on helping hotels,
restaurants,
and
nursing homes open
safely,
increase
density and
provide
a level of assurance to their customers that every effort is being
made to create a safer environment."
The
distribution agreement may be expanded with additional products and
territories in the future. Financial terms of the agreement were
not disclosed.
About
Applied UV
Applied
UV is focused on the development and acquisition of technology that
address infection
prevention in the
healthcare, hospitality, commercial and residential markets. Our
products utilize disinfection technology that applies the power of
UVC to destroy pathogens safely, thoroughly, and
automatically. The
Company's SteriLumen technology was tested at an independent
laboratory that found the SteriLumen mirror and drain to be greater
than 97% and 99.99%, respectively, effective in killing the OC43
human coronavirus, a strain of human coronavirus that is
genetically similar to SARS-CoV-2. According to the
independent laboratory, it is expected that SARS-CoV-2, the
virus that causes COVID-19 will be killed in a similar manner to
OC43. The
Company has two wholly
owned subsidiaries;
SteriLumen and Munn
Works, LLC ("Munn
Works"). SteriLumen develops
disinfection devices and technology that combat
hospital
acquired
infections (HAIs). We formed a team to solve and patent a product
and process to neutralize pathogens providing a compelling solution
for the hospitality space and a solid path to entering the
healthcare market. MunnWorks
manufactures fine mirrors specifically for the hospitality
industry. Our goal, at Munn
Works, is to contribute to
the creation of what our design industry clients seek:
manufacturing extraordinary framed mirrors.
For more
information about Applied UV, Inc., and its subsidiaries, please
visit the following websites:
https://www.applieduvinc.com/;
https://sterilumen.com/; and,
https://munnworks.com/.
About
Airocide and
Akida Holdings LLC
Akida
Holdings LLC, headquartered
in
Jacksonville, Florida, owns the exclusive
world-wide rights to a unique NASA developed
air
purification technology,
Airocide™.
The
Airocide™
technology
has been
clinically tested by the University of Wisconsin, Texas Tech
University, and Texas A&M
University. Airocide™
is listed
with the FDA as a Class II Medical
Device. Airocide's patented technology
has been proven to eliminate virtually 100% of all biological
contaminants that enter its system regardless of size
and
without
any harmful by-products.
Additional
information can be
found at
www.airocide.com.
Forward-Looking Statements
The information
contained herein may contain
"forward-looking statements." Forward-looking statements reflect
the current view about future events. When used in
this press release,
the words
"anticipate," "believe," "estimate," "expect," "future," "intend,"
"plan," or the negative of these terms and similar expressions, as
they relate to us or our management, identify forward-looking
statements. Such
statements
include,
but are not limited to, statements contained in this
press release
relating
to the view of management of Applied UV concerning its business
strategy, future operating results and liquidity and capital
resources outlook. Forward-looking statements are based on the
Company's current expectations and assumptions regarding its
business, the economy and other future conditions. Because
forward–looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ
materially from those contemplated by the forward-looking
statements. They are neither statements of historical fact nor
guarantees of assurance of future performance. We caution you
therefore against relying on any of these forward-looking
statements. Factors or events that could cause the Company's actual
results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company cannot
guarantee future results, levels of activity, performance or
achievements. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to actual results.
Applied
UV Investor Relations
TraDigital IR
Kevin
McGrath
+1-646-418-7002
kevin@tradigitalir.com
MJ
Clyburn
+1-917-327-6847
clyburn@tradigitalir.com